# Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Source: https://onco.cc/trials/nct07412613/  
OnCo record `nct07412613` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cadonilimab, CAPOX, Capecitabine in colorectal cancer, run by Akeso, now recruiting.

## Summary

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer is a phase 3 interventional study registered as NCT07412613 by Akeso, with 386 participants planned, started 2026-04-15 and due to reach its primary completion in 2030-06-15. Interventions recorded: Cadonilimab (AK104), Oxaliplatin, Capecitabine, 5- Fluorouracil, Calcium Folinate. Conditions listed: Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07412613
- Phase: 3
- Setting: A Randomized, Open-label, Controlled, Multicenter Phase 3 Clinical Trial of AK104 for Neoadjuvant/Adjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
- Sponsor: Akeso
- Enrolled: 386

## Sources

- ClinicalTrials.gov NCT07412613: https://clinicaltrials.gov/study/NCT07412613

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct07412613.json